We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App




Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience

By LabMedica International staff writers
Posted on 23 Jan 2025

Medix Biochemica (Espoo, Finland), a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, has acquired CANDOR Bioscience GmbH (Allgäu, Germany), a developer and manufacturer of premium immunoassay solutions. More...

Medix Biochemica is a market-leading, independent supplier of critical raw materials to the IVD industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. CANDOR Bioscience is a provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers, and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times. The acquisition of CANDOR Bioscience both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development.

“We are delighted to welcome CANDOR into the Medix Biochemica family,” said Steve Ferguson, CEO of Medix Biochemica. “The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team.”

“Joining forces with Medix Biochemica is an exciting milestone for CANDOR,” added Dr. Tobias Polifke and Dr. Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience. “We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry.”

Related Links:
Medix Biochemica
CANDOR Bioscience GmbH


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Ultrasonic Cleaner
UC 300 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.